Vantis Vascular, a San Jose, California-based privately held medical technology company developing performance-driven technologies for coronary interventions, has received the U.S. Food and Drug Administration (FDA) 510(k) clearance for a new 6 French (6F) model of its CrossFAST Integrated Microcatheter Advanced Delivery System.
Industry-Leading Pulse Oximetry Platform Now Features First-of-Its-Kind Atrial Fibrillation (AFib) Detection with Previously Cleared AI-Enabled Opioid-Induced Respiratory Depression (OIRD) Detection Designed Together to Deliver Earlier Clinical Insights
ATLANTA, Oct. 20, 2026 /PRNewswire/ — UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the first self-administered once-daily autoinjector administration option for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive with ZILBRYSQ® (zilucoplan).¹ The autoinjector is designed to help simplify self-administration of ZILBRYSQ, offering patients another administration option and a more convenient treatment experience.2,3
When replacing the aortic valve, a small aortic root can limit the size of the prosthetic valve that can be implanted. If the new valve is too small in relation to the patient’s body, the heart must continue to work against increased resistance—a so-called patient-prosthesis mismatch, which is associated with poorer clinical outcomes.
Thousands of heart patients could be treated without having a metal stent permanently implanted in their arteries—according to research from the University of East Anglia (UEA). A major analysis of more than 7,800 patients found that a newer treatment using drug-coated balloons performed just as well as conventional stents at preventing heart attacks and cardiovascular deaths.
In ion beam therapy, atomic nuclei are accelerated to high energies in a particle accelerator, for example, a synchrotron, and precisely directed at a tumor. There, they damage cancer cells and destroy tumor tissue. This technique is now used at several specialized medical facilities around the world, including MedAustron in Wiener Neustadt, Austria.
CORUS incorporates integrated screw fixation as a nonsegmental posterior instrumentation tool.
FLAGSTAFF, Ariz., Oct. 14, 2026 /PRNewswire/ — W. L. Gore & Associates’ medical business (Gore) today announced U.S. Food and Drug Administration approval of an expanded indication for the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) for use in fenestrated and branched endovascular aortic repair (FEVAR and BEVAR).
MENLO PARK, Calif., Oct. 14, 2026/PRNewswire/ — Maverix Medical, a company focused on revolutionizing the diagnosis and treatment of lung cancer, has augmented its console-free cryoprobe portfolio. Today the company announced that the U.S. Food and Drug Administration granted 510(k) clearance on September 2, 2026, to the Maverix Narwhal™ Pro Cryo System, the second of two flexible cryoprobes built on the same cartridge-powered architecture.
BURLINGTON, Mass., Oct. 14, 2026 /PRNewswire/ — SQ Innovation today announced that results of the SUBCUT HF II trial of its product Lasix® ONYU have been published in the Journal of the American College of Cardiology (JACC)1, one of the leading peer-reviewed journals in cardiovascular medicine.